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Zusammenfassung 
Während hämolytischer Prozesse wird Hämoglobin (Hb) aus den Erythrozyten freigesetzt. 
Extrazelluläres Hb führt zu Kreislaufinstabilität weil es Signaltransduktionsmoleküle wie 
Stickstoffmonoxid (NO) abbauen kann. Zusätzlich schädigt freies Hb das Gewebe durch 
Oxidation, besonders das Endothel. Der Mechanismus dieser Schädigung war bisher 
weitgehend unbekannt. Mit den vorliegenden Arbeiten haben wir Lipidoxidationsprodukte 
als die ultimativ toxischen Reaktionsprodukte identifiziert. Freies Hb, speziell 
Methämoglobin (Fe3+), hat ein nur lose gebundenes Häm-Molekül in der dafür vorgesehenen 
Bindungstasche. Daher kann dieses Häm leicht verloren gehen und dann in einer apolaren 
Umgebung akkumulieren, so zum Beispiel in Lipoproteinen oder Zellmemebranen. Darin 
kann Häm die Lipidperoxidation unter Bildung von Lipidoxidationsprodukten exponentiell 
steigern, was schlussendlich zur Toxizität auf die Endothelzellen führt. Wir haben 
Haptoglobin (Hp) als potenten Inhibitor der Hb Toxizität identifiziert. Hp bindet irreversibel 
an Hb und bildet einen stabilisierenden Komplex, welcher den Hämverlust zuverlässig 
verhindert. Ferner haben wir mit Hämopexin (Hx) einen zweiten Inhibitor der Hb-Toxizität 
gefunden. Im Gegensatz zu Hp bindet Hx jedoch nicht an Hb, sondern fängt freies Häm mit 
sehr hoher Affinität ein und verhindert dadurch den Hämtransfer in die Liposomen. Weitere 
in-vivo und später klinische Studien sind notwendig, um die protektive Potenz von Hp und 
Hx basierend auf diesen fundamentalen biochemischen und zellbiologischen Prozessen zu 
bestätigen. 
 
 
Abstract 
Hemoglobin (Hb) is released from red blood cells during hemolysis. Extracellular Hb causes 
vascular instability due to depletion of small signal transduction molecules such as nitric 
oxide. Free Hb also leads to oxidative tissue damage especially on the endothelium: 
However, the mechanism of this damage was poorly characterized. In the present work, we 
identified lipid oxidation products as the ultimate toxic reaction species. In free Hb, 
especially in its ferric redox state (Fe3+), heme is only loosely bound in the heme pockets 
and thus can easily be released. Free heme accumulates in an apolar milieu such as in 
liposomes or cell membranes. Inside liposomes, heme is able to exponentially accelerate 
lipid peroxidation and thus formation of lipid oxidation products, finally exerting endothelial 
toxicity. We have identified haptoglobin (Hp) as a potent inhibitor of Hb toxicity. Hp binds 
Hb irreversibly and thus forms a stabilizing complex that completely inhibits heme release. 
We have further found Hemopexin (Hx) as a second potent inhibitor of Hb oxidative toxicity. 
Hx, in contrast to Hp, does not bind to Hb but encapsulates free heme at very high affinity 
and thus prevents translocation of Hx into liposomes. The specific target-specificities of Hp 
and Hx, respectively, provide a biochemical explanation for the enigmatic description of Hp 
as the primary and Hx as the backup protection system against Hb toxicity. Subsequent in-
vivo and later clinical studies are necessary to confirm the protective potency of Hp and Hx 
with further data based on the fundamental biochemical and cell biological mechanics 
identified within this thesis. 
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Introduction 
Hemoglobin (Hb) is released from red blood cells during multiple disease states, including 
hereditary hemolytic anemia (e.g. hereditary spherocytosis, sickle cell disease), acquired 
hemolytic anemia (e.g. autoimmune hemolytic anemia, paroxysmal nocturnal 
hemoglobinuria), infection triggered hemolysis (malaria, hemolytic uremic syndrome and 
also generally during sepsis), mechanical red blood cell destruction (e.g. artificial heart 
valves, extracorporeal circulation) as well as during massive blood transfusion (Figure 1). In 
these conditions, extracellular Hb is both a disease marker and a toxin5. Hemolysis can also 
occur in anatomically defined microscopic regions such as sites of tissue injury, 
inflammation or within atherosclerotic plaques. Depending on the scale and rate of the 
hemolytic process, the primary adverse effects that occur during acute and chronic Hb 
exposure are vascular dysfunction, oxidative tissue damage and deregulated inflammation6. 
These effects can lead to systemic manifestations such as as pulmonary arterial 
hypertension, renal failure, neuro- and cardiac toxicity (including congestive cardiac failure 
and acute chest syndrome)7 but also to more localized processes such as progression and 
destabilization of atherosclerotic plaques.  
Several pathways of Hb mediated endothelial toxicity have been identified: Oxidation of 
Figure 1: Causes of hemolysis. (A) Under physiologic conditions Hb is concealed within 
erythrocytes. (B) With atherosclerosis, hemolysis can occur inside the plaque as well as in the now 
narrowed lumen. (C) During autoimmune hemolytic anemia Hb are opsonized by anti-erythrocytic 
autoantibodies and then destroyed by complement activation. (D) artificial heart valves and other 
mechanical devices in the blood stream cause continuous hemolysis by shearing erythrocytes 
beyond their resistance. (E) intraerythrocytic parasites such as plasmodia cause hemolysis by altering 
the intracellular homeostasis. (F) overaged blood transfusion as well as (G) erythrocytopathies such 
as hereditary spherocytosis or ellipsocytosis cause intravascular hemolysis by altering membrane 
flexibility and thus diminishing erythrocytic elasticity. (H) During inflammation, activated immune cells 
cause direct hemolysis by producing reactive oxygen species. 
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 ferrous Hb to metHb (Fe2+ à Fe3+ + e-), either by autoxidation or driven by external oxidants 
such as hydrogen peroxide (H2O2) or lipid peroxide radicals (LOO•) causes heme-globin 
binding to drastically decline, leading to externalization of free heme. Free heme is cytotoxic 
by causing oxidative damage to cellular proteins and lipids and impairs cellular homeostasis 
of damaged proteins by interfering with proteasomal activity. Externalized heme, due to its 
lipophilic nature, will compartmentalize into the oily phase such as into lipids where it starts 
a radical driven oxidation of unsaturated fatty acids eventually leading to formation of 
cytotoxic metabolites. If metHb is further oxidized by external oxidants, it reaches the ferryl-
Hb oxidation state (Fe3+ + •O- à Fe4+=O2- + Porphyrin•+ + e-), a Hb species with so high 
Figure 2: Attenuation of Hb toxicity by the plasma proteins Haptoglobin (Hp) and Hemopexin 
(Hx). (A) OxyHb undergoes auto-oxidation to metHb. In the presence of oxidative substances such 
as hydrogen peroxide (H2O2), this oxidation is acceleration and the even higher oxidated Hb species 
ferryl-Hb (Fe4+=O2-) is generated. (B) Ferryl-Hb can oxidate its globin chains causing protein 
denaturation and ultimately globin precipitation alongside with heme release. This globin-precipitate 
triggers endothelium inflammation and thus disruption of the endothelial monolayer. (C) Even without 
the presence of oxidative substances, metHb can release its heme due to only loose binding. Free 
heme has a direct cytotoxic effect by protein oxidation and inhibition of the damaged proteins 
disposal by inhibiting the proteasome leading to accumulation of oxidized proteins. (D) Free heme 
also is, due to its hydrophobic character, transferred into liposomes and initiates a oxidative chain 
reaction involving unsaturated fatty acids, ultimately generating toxic oxidized lipid metabolites. (E) 
Hp structurally stabilizes Hb in all its oxidation states. Especially ferryl-Hb is stabilized by Hp in such 
a way, that globin oxidation and subsequent denaturation is completely inhibited. (F) Also Hp binds 
metHb in such a way, that heme binding is massively improved, preventing the initiation of the 
vicious lipid peroxidation cycle triggered by released heme. (G) Hx has no direct binding affinity to 
Hb, however, it has a extremely high binding affinity to free heme, capturing heme before it can 
transfer into the liposomal compartment thus also preventing lipid peroxidation triggered by heme. 
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oxidative power, that the porphyrin radical can actually delocalize to aromatic amino acids 
of the globin chain causing globin oxidation and finally denaturation22 
Haptoglobin and its phenotypes as scavenger proteins 
Haptoglobin (Hp), a natural Hb-binding plasma proteins in mammals, binds extracellular Hb 
dimers in an irreversible large complex10 that can be cleared by CD163+ macrophages and 
monocytes11. Hp is present in human plasma at high concentration of about 2g/l equaling 
80µM of heme binding capacity and binds Hb with very high affinity. Binding of Hb to Hp 
appers to fundamentally alter its potential to induce pathophysiology by sequestering the 
Hb:Hp complex within the intravascular compartment and thereby limiting tissue exposure; 
by stabilizing the redox chemistry and the structure of bound Hb; and by preventing the 
release of heme when Hb is oxidized to metHb (ferric state, Fe3+). Preclinical studies 
suggest a strong therapeutic potential for Hp infusion in conditions with enhanced 
intravascular hemolysis6,12. The use of Hp as treatment modality is also supported by clinical 
experience with human plasma-derived Hp products approved for use in Japan13. 
Hp is composed of two different chains, Hpα and Hpβ. While the Hpβ-chain binds a Hbα-
Hbβ-dimer, the Hpα-Chain links the Hp molecule together. There are two different forms of 
Hpα in humans: Hpα1 forms one disulfide bond to another Hpα-chain while Hpα2 can form 
two disulfide bonds. In case of the phenotype Hp1-1, where in both alleles the Hpα1-Gene is 
present, Hp-heterodimers in the form of (Hpα1)2(Hpβ)2 are formed. In case of the phenotype 
Hp2-2, where in both alleles the Hpα2-Gene is present, circles of Hp-polymers are formed 
with varying molecular mass in the form of (Hpα2)n(Hpβ)n where n>2. In the case of Hp1-2, 
both Hp-genes are present and next to both Hp-forms present in Hp1-1 and Hp2-2 
condition also linear Hp-polymers in the form of (Hpα1)2(Hpα2)n(Hpβ)n+2 where n>0 are 
formed. In our study we showed that Hp1-1 and Hp2-2 are both effective in vivo and in 
guinea pigs to attenuate hemoglobin toxicity1. We found no differences between the two 
phenotypes in Hb binding and intravascular compartmentalization of Hb in vivo. Both 
attenuate Hb-induced blood pressure response and renal iron deposition. Also, Hb 
oxidation was not found to be different between the phenotypes, the most oxidized ferryl 
(Fe4+) Hb redox state was stabilized, heme was retained within the complex in the ferric 
(Fe3+) condition and Hb-driven low-density lipoprotein peroxidation was prevented. Thus, we 
concluded that both Hp phenotypes provide equal biochemical and biological protection 
from Hb toxicity in vitro and in vivo. 
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 Hb pseudoperoxidase activity 
Under peroxidative stress by external hydrogen peroxide we identified globin oxidation and 
subsequent denaturation as a principal mechanism of oxidative Hb toxicity on endothelial 
cells. Human Hb is structurally so labile that oxidation by ferryl formation (Fe4+=O2-) causes 
aggregation and precipitation of the globin (Figure 3). We could correlate this precipitate 
with endothelial inflammation and toxicity2. In contrast to human Hb, bovine Hb also reacts 
with H2O2 by ferryl formation, however, no aggregation and no endothelial inflammation or 
toxicity can be observed. Also structurally stabilized human Hb, covalently cross-linked 
between the two Hbα-Chains, shows no precipitation and also does not induce the 
Figure 3: Hb precipitation by oxidation. (a) Aggregate formation during the reaction of hydrogen 
peroxide generated by glucose oxidate (GOX) 2.5mU/l with Hb at 125µM was recorded by time-
resolved spectrophotometry at 700nm under identical conditions as the ECIS-experiment with 
HPAEC shown in (b). At equal H2O2 exposure, endothelial barrier function was compromised in the 
presence of human Hb bot nut in the presence oft he structure-stable alpha-crosslinked Hb ( XLHb) 
or bovine Hb. The addition of Hp (isostoechiometric) tot he huHb + GOX-Reaction completely 
prevented aggregate formation and endothelial barrier breakdown. (c) The aggregates/precipitated 
can be localized on HPAEC by SEM (the images were recorded after 5h) No aggregates can be seen 
in the presence of Hp. (This figure is part of publication 2). 
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endothelial response observed without cross-linking. Finally, we could show that Hb bound 
to Hp also shows no precipitation and no endothelial toxicity. Hp is thus able to attenuate 
this principal pathway of peroxidative endothelial Hb toxicity.  
By binding to Hp, Hb is structurally stabilized in such a way that the instable high-oxidation 
state ferryl-Hb (Fe4+=O2-) is concealed and the porphyrin radical produced during ferryl 
formation can be scavenged within the protein complex. This prevents the malicious Hb 
globin oxidation and denaturation and also prevents the formation of the toxic globin 
denaturation product. We could measure ferryl decay as an indicator for radical 
externalization and degradation by kinetic spectrophotometry and spectral deconvolution.. 
We determined the ferryl decay rate and found that Hp1-1 as well as Hp2-2 both are able to 
Figure 4: Hp stabilizes the Hb ferryl state. (A) oxy-Hb (12.5µM) with or without Haptoglobin of both 
phenotypes was incubated with 40mU of glucose-oxidase (GOX) as a source of continuous H2O2 at 
37°C. The absorbance over a wavelength range of 300-700nm was recorded during 5h. The amounts 
of different Hb reaction products were extracted by spectral deconvolution. While Hp1-1 and Hp2-2 
complexes of Hb indicate identical reaction patterns over time, free Hb shows a more rapid decline 
of ferryl-Hb concentrations (red line) with a concurrend more rapid increase of structurally nondefined 
porphyrin degratdation products (black line). (B) Ferryl decay rates (k2) over a range of GOX 
concentrations. Experimental design and readout was shown in (A). Red: unbound Hb, blue: Hb:Hp1-
1, gray: Hb:Hp2-2. The plotted line represents a linear regression ± 95% confidence interval (N=3 
experiments). (C) identical experiments were repeated with 200nM of bovine catalase added after the 
first 12min. The recordings demonstrate that, in the presence of both Hp phenotypes, ferryl-Hb is 
much more stable compared to free Hb. (This figure is part of publication 1) 
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 significantly increase ferryl stability (Figure 4)1. This mechanistically explains the attenuation 
of formation of denatured globin products by Hb peroxidation by Hp. 
By oxidizing oxyHb (Fe2+) to metHb (Fe3+) also 
heme binding is altered. While heme is tightly 
bound to the globin in oxyHb, in metHb heme is 
only loosely bound in the heme pocket and can 
easily be released. By measuring the transfer to 
Hemopexin (Hx), an abundant plasma protein 
with very high heme affinity by 
spectrophotometry, we could determine the 
heme transfer-rate as 3.51s-1. By binding to Hp, 
heme binding of metHb is strongly improved 
and transfer-rates decrease to 0.05s-1 for Hp1-1 
and 0.07s-1 for Hp2-2, respectively. Also during 
globin oxidation by oxidating Hb with H2O2,  
heme is ultimately released.  
Free heme toxicity 
Free heme itself shows direct cellular toxicity3. 
We could identify two synergistic mechanisms 
of heme toxicity (Figure 5): First, heme inhibits 
the proteasome, the intracellular garbage 
collection and degradation system. Proteins are 
marked for degradation by ubiquitination. We 
could show that heme causes accumulation of 
ubiquitinated proteins as well as the ubiquitin 
adaptor protein sequestosome (Sqstm1). Heme 
inhibits the enzymatic activity of the 26S-
proteasome in a dose-dependent manner by 
direct binding to this protein. Second, heme 
directly oxidizes proteins and causes covalent 
protein-protein crosslinking and protein-lipid 
crosslinking products. These oxidative protein 
degradation products are potentially cytotoxic 
and are normally disposed by the ubiquitin-
Figure 5 Direct heme toxicity: (A) Anti-myc 
western blot of Sqstm1-myc expressed 
under a constitutive CMV promoter in stably 
transfected RAW-264 cells to a range of 
heme concentrations. Sqstm1-myc 
accumulates with increasing heme 
concentration. (B) Effect of heme and 
proteasome inhibitor bortezomib (100pM) 
treatment for 6h on the accumulation of an 
ubiquitin-tagged fluorescent protein 
(ZsGreen) expressed in HEK-293 cells. 
Proteasomal degradation is inhibited by 
heme and bortezomib (positive control). (C) 
Enzymatic activity of purified 26S 
proteasome with increasing concentrations 
of heme as assessed by monitoring the 
release of fluorescent AMC from the 
proteasome substrate peptide Suc-LLVT-
AMC. Bortezomib, a proteasome inhibitor,  
(Bor) at a concentration of 100pM was used 
as a positive control. (D) Hmox1 (-/-) MEFs 
were incubated with different metal 
protoporphyrins (PP) for 18h. Expression of 
Sqstm1 protein was probed by western blot. 
Accumulation of Sqstm1 and high-molecular-
weight Sqstm1-protein aggregates in cells 
treated with FePP and CoPP can be 
observed. However, CoPP has not oxidative 
activity whereas FePP shows not only 
proteasomal inhibition but also protein 
oxidation followed by aggregation. (This 
figure is part of publication 3) 
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sequestosome-proteasome pathway. Due to blockage of this pathway, degradation of these 
products is impaired, leading to a synergistic effect of the two mechanisms of direct heme 
toxicity. 
Hb toxicity caused by lipid peroxidation 
Because endothelial Hb toxicity may not be dependent of an external oxidator, we designed 
a model that allowed us to observe cellular effects in parallel to exact biochemical 
measurements in the absence of an exogenous oxidant such as H2O2. In the described 
previous works, we repeatedly identified oxidized lipoprotein as potential mediators of Hb 
toxicity after addition of human low-density lipoprotein (LDL). However, human LDL is not a 
homogenous compound, it contains β-carotene, a strong lipophilic antioxidant, in inter- and 
intraindividually varying amounts and also the lipid composition is not constant. Therefore, it 
is not feasible for systematic experimentation. As a replacement, we used a reconstituted 
lipoprotein (rLP) labored from apoA1-lipoprotein purified from human plasma in an artificial 
liposome together with soy bean lecithin (CSL-11120,21). This particle has similar physical and 
chemical properties to human lipoproteins but is biochemically well defined, contains no 
antioxidants and thus enables reproducible results. 
We biochemically characterized our rLP 
model by spectrophotometry. If oxyHb 
(10µM) and rLP (0.5g/l) are mixed, after a 
defined and well reproducible time, a 
sudden desaturation of oxyHb occurs after 
about tdes=18min at 37°C (Figure 6). After 
desaturation the build up of oxidized Hb 
species can be observed and lipid 
oxidation products can be detected. To 
characterize lipid oxidation we used a 
TBARS-Assay (thiobarbituric acid reactive 
substances) for quantification and mass 
spectrometry for identification as well as 4-
HNE (4-hydroxynonenal) adducts as independent verification. We then used our system 
with endothelial cells in an ECIS (electrical cell substrate impendance sensing) setup and 
observed endothelial toxicity (defined as 50% decline in transendothelial resistance) after a 
few hours. 
Figure 6: Time course of different Hb 
oxygenation and oxidation states during the 
reaction of oxyHb with rLP (rLP 0.5g/l, Hb 10µM, 
PBS pH 7.4, 37°C) as observed by 
spectrophotometry and spectral deconvolution. 
The Hb desaturation time (tdes) is indicated by the 
green triangle. (This figure is part of publication 4) 
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 We found, that tdes can be shortened by replacing oxyHb by more readily available heme 
such as in the form of metHb or even by directly adding free heme to the system. We also 
found that tdes changed reciprocal to the starting heme concentration. We further found that 
antioxidants could slow down or even inhibit the reaction, however this effect was most 
pronounced if a lipophilic antioxidant such as butylated hydroxytoluene was used instead of 
a hydrophilic species such as ascorbic acid. This observation lead to the hypothesis, that 
free heme, a lipophilic molecule, has to transfer into the rLP compartment where it triggers a 
radicalic lipid oxidation in form of a self-enforcing chain reaction via heme-catalized 
formation of lipid peroxides: While without heme, lipid-autoperoxidation is very slow, 
(virtually a zero-order kinetic only dependent of the starting concentration of lipid radicals 
which is usually very low), heme accelerates the peroxidation exponentially to a chain 
reaction because it can generate two new lipid radicals out of one lipid peroxide. This also 
explains why free heme or metHb show a much faster tdes than oxyHb: While heme in oxyHb 
is tightly bound inside the heme pocket, metHb only loosely captures heme inside the 
pocket making it readily available. OxyHb has to auto-oxidate to metHb in order to start the 
reaction which is rate-limiting step in this model.  
We used this rLP model to extensively study the role of Hp and Hx as a protective system 
against Hb-driven oxidative damage. Hp binds irreversibly to Hb, forming the very stable 
Hb:Hp complex. Although susceptibility to oxidation from ferrous to ferric state is not 
significantly altered by Hp, ferric Hb:Hp encapsulates heme very firmly and virtually no 
heme is released even in the oxidated metHb-state2. This protective mechanism only works, 
however, if all available Hb is complexed to Hp; otherwise some heme will always be 
released and begin its vitious cycle. Hp thus protects in a spatial way. Hx on the contrary 
does not bind to Hb at all. Because of its very high affinity to heme, it will bind all heme 
released from metHb as long as native apoHx is available. Thus, Hx can prevent Hb toxicity 
at already low substoechiometric levels relative to Hb, although only for a limited time (the 
protection is temporary). This mechanism explains the molecular basis for the observation 
that during hemolysis the first line of defense is Hp, which is readily depleted, followed by 
the second line of defense Hx, which only decreases after Hp has been exhausted. 
To demonstrate the spatial protection of Hp and the temporal protection of Hx, we used the 
rLP system in parallel to measure tdes as a marker of the biochemical effect of heme-
catalyzed lipid peroxidation and loss of transendothelial resistance as a surrogate of 
endothelial toxicity. We could show, that hemopexin prolongs endothelial survival as well as 
tdes directly proportional to the molar ratio to Hb (Figure 7). This is explained by the heme-
capturing mechanism of endothelial protection by Hx. While oxyHb slowly auto-oxidizes to 
12
 
 
metHb, Hx immediately extracts heme out of newly formed metHb and prevents transfer 
into rLP, halting the reaction for a limited period of time if used in sub-stoichiometric ratio to 
Hb. In contrast to Hx, Hp shows virtually no protective effect if used in sub-stoichiometric 
amounts relative to Hb, explained by the spatial protection mechanism: Only of every Hb 
molecule is bound to Hp a heme release can be certainly inhibited. And only in this 
condition transfer of heme into rLP and subsequent firing up of the heme-catalized lipid-
peroxidation can be prevented.  
Figure 7: Stoichiometric requirements for protection by Hp and Hx. 10µM 10µM oxyHb where 
reacted with 0.5g/l rLP in the presence of Hx (upper graphs) or Hp (lower graphs) over a range of Hb 
binding protein concentrations between 0% and 100% binding capacity relative to heme. OxyHb 
concentrations was measured by spectrophotometry and spectral deconvotlution. In the left graphs, 
time to Hb desaturation of each sample is plotted against Hb binding protein capacity of Hx and Hp, 
respectively. Identical reactions were performed in HUVEC cell culture and transendothelial electrical 
resistance was measured by ECIS. In the right panels, the time to loss fo 50% of the resistance was 
plotted against the Hb binding capacity of Hx and Hp, respectively. (This figure is (a modified) part of 
publication 4) 
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 Conclusions and Outlook 
We have identified oxidation of lipoproteins and subsequent endothelial damage as a major 
pathway of Hb toxicity. Heme release from oxidized Hb, followed by transfer of Heme into 
liposomes and induction of a radicalic lipid oxidation cycle producing cytotoxic lipid 
degradation products are the key steps of endothelial Hb toxicity. Additional to toxicity via 
lipid degradation products, we could show that heme also has a direct cytotoxic activity by 
inhibiting cellular degraded protein disposal via the proteasome. This effect is potentiated 
by the ability of heme to directly oxidize proteins; this leads to an intracellular accumulation 
of degraded, oxidized proteins by both, increased production and impaired removal.  
We have extensively studied the protective activity of the natural Hb scavenger Hp. We 
could show, that both phenotypes Hp1-1 and Hp2-2 inhibit oxidative Hb degradation and 
heme release extremely effective. Further we could show, that both phenotypes exert this 
protective effect not only in biochemical assays but also in vitro and in vivo. Because Hp not 
only binds to Hb with high affinity but also structurally stabilizes the complex in such a way 
that heme release, protein oxidation (but not heme oxidation) are inhibited, heme is never 
released from Hp bound Hb and thus the toxicity described above can not evolve.  
Although Hx has been identified as a protein being consumed during hemolysis and also as 
a possible protective agent in Hb toxicity, the significance of this effect could not be 
coherently explained since Hx can only bind to free heme but not directly to Hb. By 
identifying heme release as the rate limiting and crucial step in Hb toxicity, we where able to 
integrate Hx into the model of Hb toxicity and explain its protective role. Because Hx has an 
extremely high affinity to free heme, this protein is able to capture heme being released 
directly after it leaves Hb and thus preventing transfer into the liposome. Since exactly this 
transfer is the crucial step for the development Hb toxicity, Hx is an extremely potent and 
effective inhibitor thereof. 
The different modes of protection of Hp and Hx explain their sequential decline during 
hemoglobinemia: As long as less free Hb is available than Hp is present, Hp binds all Hb, 
inhibits heme release and facilitates sequestration of Hb by CD163+ macrophages. The 
situation changes as soon as the available Hp is saturated with Hb and even more Hb is 
released. In this situation Hx acts as a backup system by directly capturing released heme. 
The advantage of directly capturing free heme is, that only substoichiometric amounts of Hx 
are necessary in relation to free Hb since only the heme released from Hb has to be covered 
by Hx and not every Hb molecule as it is the case for Hp. 
14
 
 
With this cumulative work, we have further explained the mechanisms of endothelial Hb 
toxicity via heme release and heme-mediated lipid oxidation. We have also shown and 
explained the protective roles and effects of the plasma proteins Hp and Hx. These results 
are however limited to endothelial toxicity; the mechanisms Hb toxicity on other tissues and 
organs such as the kidney remain to be explored, although a heme-mediated effect could 
be postulated based upon our data. Also the significance of heme mediated endothelial Hb 
toxicity in the overall context of the systemic toxicity of Hb, which for instance also includes 
vasoconstriction by NO depletion, is to be demonstrated in further in vivo studies. 
Because Hp as well as Hx are natural plasma proteins, they are readily available since 
efficient plasma fractionation methods exist for both; and due to their intrinsic nature also 
toxicity or anaphylactic reactions are unlikely. Subsequent in-vivo and later clinical studies 
are necessary to confirm the protective potency of Hp and Hx with further data based on 
the fundamental biochemical and cell biological mechanics identified within this thesis. 
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Authorship contribution of Jeremy Werner Deuel (JWD) to the 
publications that are part of the cumulative PhD thesis 
 
Publication 1: Human Hp1-1 and Hp2-2 phenotype-specific haptoglobin therapeutics 
are both effective in vitro and in guinea pigs to attenuate hemoglobin toxicity. 
JWD described the spectrophotometric method to simultaneously measure the different 
oxidation states of Hb and thus have measured the stability of the ferryl state of Hb and 
Hb:Hp complex (Figure 7) and modeled the decay rate according to the description in the 
methods section ("Spectral analyses of Hb H2O2 reactions"). He further developed the 
method to spectrophotometrically determine heme release from metHb and metHb:Hp 
complex (Figure 8B) and has performed the other spectrophotometric studies depicted in 
Figure 8A, C and D. JWD also developed the metHb decay model and thus quantified 
metHb decay resulting from heme transfer to hemopexin as shown in Table 1 and in the 
methods section ("Hb.Hpx heme transfer"). 
JWD co-first author together with Miriam Lipiski of this paper. He developed the methods 
and performed the experiments and analysis for the biochemical characterization of Hb, 
Hb:Hp1-1 and Hb:Hp2-2 complexes. 
Publication 2: Mechanisms of haptoglobin protection against hemoglobin peroxidation 
triggered endothelial damage. 
JWD quantified precipitation of different Hb by spectrophotometry (Fig 2A) under 
continuous oxidation by H2O2 produced by glucose oxidase. JWD developed a 
spectrophotometric method to absolutely quantify different Hb oxidation species in real-
time during a reaction of Hb with H2O2 as shown in Figure 3A, B and C, thus making it 
possible to monitor and characterize the different Hb oxidation state and measure the 
stability of the ferryl state. 
JWD is co-first author, together with Christian A. Schaer, of this paper. JWD developed the 
method to absolutely quantify the different Hb reaction species (oxyHb, desoxyHb, metHb 
and ferrylHb as well as degradation products) in real-time by spectrophotometry in the 
visible range by fitting extinction curves of the different species using the non-negative least 
squares algorithm. This allowed to develop the biochemical foundation of this paper and 
thus—together with the cell biology data—identify the toxic and non-toxic metabolites of Hb 
peroxidation. 
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 Publication 3: Proteasome inhibition and oxidative reactions disrupt cellular 
homeostasis during heme stress. 
RAW-264 cells were stably transfected by JWD with sqstm1-myc expressed under a 
constitutive CMV promoter and measured SQSM1 retention after incubation with heme to 
prove that not only induction but also impaired degradation of sequestosome is an effect of 
heme toxicity (Figure 3G) as well of cobalt-protoporphyrin (Fig 7B). He also measured 
retention of ZsGreen-Ubiquitin in HEK-293 cells after incubation with heme and bortezomib, 
again showing that proteasome inhibition and thus accumulation of ubiquitin tagged 
proteins is a heme effect (Figure 4B). A fluorescent proteasome activity assay using Suc-
LLVT-AMC was developed and used by JWD, showing proteasomal inactivation by heme in 
a biochemical model (Figure 4D). The independence of the presence of an antioxidant for 
proteasomal inhibition (Figure 7G) was also demonstrated by him. 
In summary, JWD contributed to the mechanistic proof that heme inhibits proteasomal 
activity and thus ubiquitinated proteins and sequestosome are retained by setting up a 
proteasome activity assay and a cellular model of sequestosome and ubiquitin retention. 
Publication 4: Different target specificities of haptoglobin and hemopexin define their 
sequential role as a primary and backup protective system against hemoglobin 
toxicity. 
JWD and Dominik J. Schaer designed the experiments and wrote this paper. JWD 
performed the experiments on cellular biology on vascular endothelial cells (Figures 1D, 2, 
3D and 6B), but also performed most of the biochemical analyses. He measured Hb redox 
state during reaction with rLP (Fig 3A), verified the measurements by direct O2 measurement 
and correlation with the spectrophotometric data (Fig 3B), and did all the studies involving 
Hb deoxygenation (Fig 5 and 6A) as well as TBARS quantification (Fig 7A). Together with 
Michele Puglia he analyzed the mass spectrometry data and thus identified oxidized lipids 
(Figures 4A and 4C). Also the explanatory models and the corresponding figures explaining 
our hypothesis and findings (Figure 1E, 3C and 7B) where designed by JWD. 
This is the paper resulting from the experiments in conjunction with the hypotheses 
presented in the application to the MD-PhD-programs. 
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